ArticleThe oncologist2025
The prognostic value of sarcopenia and sarcopenic obesity in patients with lung cancer receiving immunotherapy: a propensity score matching study.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Impact of body mass index on progression-free survival and endocrine immune-related adverse events in advanced NSCLC patients treated with nivolumab: A retrospective cohort study.Northern clinics of Istanbul · 2026Article
- Postoperative pain score and infection risk in lung cancer resection: a propensity score-matching study.American journal of translational research · 2026Article
- Association between depression and low skeletal muscle mass in patients with newly diagnosed lung cancer.Frontiers in psychology · 2026Article
- Article
- Association of Skeletal Muscle Radiodensity and Skeletal Muscle Index with Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer.Muscles (Basel, Switzerland) · 2025Article
- Immune checkpoint inhibitor-induced toxicity: a real-world analysis of the role of BMI.Frontiers in oncology · 2025Article
- The relationship between sarcopenic obesity and cognitive functionality among inpatients with stable schizophrenia.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSarcopenic obesity (SO) is a prognostic factor and its impact on response to immunotherapy is still unknown in lung cancer. We aimed to explore the role of SO and body composition in predicting overall survival (OS) in patients with lung cancer receiving immune checkpoint inhibitors (ICIs).
methodsWe conducted a retrospective study involving 119 patients with lung cancer who underwent immunotherapy. The subcutaneous fat area (SFA), visceral fat area (VFA) and skeletal muscle index (SMI) were determined by the cross-sectional computed tomography at the L3 lumbar vertebral level. Sarcopenia and SO were defined by SMI and body mass index. Kaplan-Meier and Cox proportional hazard analyses were used to evaluate the impact of body composition on survival. The propensity score matching (PSM) analysis was used to reduce bias and a nomogram was created to predict the OS.
resultsThe Kaplan-Meier survival showed that patients with sarcopenia and SO had poor survival time in the total and PSM cohort. The Cox analyses revealed that sarcopenia (Hazard ratio (HR): 2.04, 95% Confidence Interval (CI): 1.04-4.01, P = 0.039) and SO (HR: 3.17, 95%CI: 1.49-6.75, P = 0.003) were independent OS predictors. SFA and VFA were not associated with OS. The SMI, age, stage, albumin level and SFA were used to develop a nomogram. Patients with high nomogram scores had worse OS (P < 0.0001).
conclusionsSarcopenia and SO are prognostic factors in patients with lung cancer receiving ICIs. A nomogram that integrates body composition is sufficiently accurate for predicting OS in patients with lung cancer receiving immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.